FDA Approved Products
1,302 products with lifecycle intelligence, competitive pressure scores, and patent timelines.
ANNOVERA
segesterone acetate and ethinyl estradiol
Peak
VAGINAL · RING
pregnancy
2018
NDA0/100
ANTARA (MICRONIZED)
fenofibrate
Peak
ORAL · CAPSULE
severe hypertriglyceridemia (TG greater thanequal to 500 mg/dL) ()+5
2004
NDA0/100
APADAZ
benzhydrocodone and acetaminophen
Peak
Zevra Therapeutics
ORAL · TABLET
2018
NDA0/100
APONVIE
aprepitant
Peak
Heron Therapeutics
INTRAVENOUS · EMULSION
postoperative nauseavomiting (PONV) in adults
2022
NDA0/100
APRETUDE
cabotegravir
Peak
GSK
INTRAMUSCULAR · SUSPENSION, EXTENDED RELEASE
2021
SMNDA0/100
APTIOM
eslicarbazepine acetate
Peak
Sumitomo Dainippon Pharma
ORAL · TABLET
partial-onset seizures in patients 4 years of ageolder
2013
NDA0/100
AQVESME
mitapivat
Peak
Agios Pharmaceuticals
ORAL · TABLET
anemia in adults with alpha-beta-thalassemia+1
2022
NDA0/100
ARAKODA
tafenoquine
Peak
ORAL · TABLET
malaria in patients aged 18 yearsolder
2018
NDA0/100
ARAZLO
tazarotene
Peak
Bausch + Lomb
TOPICAL · LOTION
2019
NDA0/100
ARIKAYCE KIT
amikacin
Peak
Insmed
INHALATION · SUSPENSION, LIPOSOMAL
no alternative treatment optionsfor the treatment of Mycobacterium avium complex (MAC) lung disease
2018
NDA0/100
ARISTADA
aripiprazole lauroxil
Peak
Alkermes
INTRAMUSCULAR · SUSPENSION, EXTENDED RELEASE
schizophrenia in adults ()schizophrenia
2015
NDA0/100
ARISTADA INITIO KIT
aripiprazole lauroxil
Peak
Alkermes
INTRAMUSCULAR · SUSPENSION, EXTENDED RELEASE
schizophrenia
2018
NDA0/100
ARMONAIR DIGIHALER
fluticasone propionate
Peak
Teva
INHALATION · POWDER
these symptoms of hay feverother upper respiratory allergies:
2017
NDA0/100
ARMONAIR RESPICLICK
fluticasone propionate
Peak
Teva
INHALATION · POWDER
these symptoms of hay feverother upper respiratory allergies:
2017
NDA0/100
ARTESUNATE
artesunate
Peak
Amivas
INTRAVENOUS · POWDER
2020
NDA0/100
ARYMO ER
morphine sulfate
Peak
ORAL · TABLET, EXTENDED RELEASE
severepersistent pain+1
2017
NDA0/100
ASPRUZYO SPRINKLE
ranolazine
Peak
ORAL · GRANULES, EXTENDED RELEASE
chronic angina
2022
NDA0/100
ATORVALIQ
atorvaliq
Peak
ORAL · SUSPENSION
type 2 diabetes mellitusheart failure
2023
NDA0/100
AUBAGIO
teriflunomide
Peak
Sanofi
ORAL · TABLET
relapsing forms of multiple sclerosis (MS)to include clinically isolated syndrome+3
2012
NDA0/100
AUSTEDO
deutetrabenazine
Peak
Teva
ORAL · TABLET
2017
NDA0/100
AUSTEDO XR
deutetrabenazine
Peak
Teva
ORAL · TABLET, EXTENDED RELEASE
2023
NDA0/100
AUVELITY
dextromethorphan hydrobromide, bupropion hydrochloride
Peak
Axsome Therapeutics
ORAL · TABLET, EXTENDED RELEASE
major depressive disorder (MDD) in adults
2022
NDA0/100
AUVI-Q
epinephrine
Peak
INTRAMUSCULAR, SUBCUTANEOUS · SOLUTION
2012
NDA0/100
AVYCAZ
ceftazidime, avibactam
Peak
AbbVie
INTRAVENOUS · POWDER
the following infections caused by designated susceptible Gram-negative microorganisms in adultused in combination with metronidazole ( ) Complicated Urinary Tract Infections (cUTI)+20
2015
NDA0/100